| Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints J Bartkova, N Rezaei, M Liontos, P Karakaidos, D Kletsas, N Issaeva, ... Nature 444 (7119), 633-637, 2006 | 2319 | 2006 |
| Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer R Di Micco, G Sulli, M Dobreva, M Liontos, OA Botrugno, G Gargiulo, ... Nature cell biology 13 (3), 292-302, 2011 | 402 | 2011 |
| Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation M Ogrunc, R Di Micco, M Liontos, L Bombardelli, M Mione, M Fumagalli, ... Cell Death & Differentiation 21 (6), 998-1012, 2014 | 335 | 2014 |
| Factors contributing to inappropriate ordering of tests in an academic medical department and the effect of an educational feedback strategy S Miyakis, G Karamanof, M Liontos, TD Mountokalakis Postgraduate medical journal 82 (974), 823-829, 2006 | 319 | 2006 |
| Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39) KN Moore, M Bookman, J Sehouli, A Miller, C Anderson, G Scambia, ... Journal of Clinical Oncology 39 (17), 1842-1855, 2021 | 261 | 2021 |
| Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior M Liontos, M Koutsami, M Sideridou, K Evangelou, D Kletsas, B Levy, ... Cancer research 67 (22), 10899-10909, 2007 | 246 | 2007 |
| Mutant p53 enhances nuclear factor κB activation by tumor necrosis factor α in cancer cells L Weisz, A Damalas, M Liontos, P Karakaidos, G Fontemaggi, ... Cancer research 67 (6), 2396-2401, 2007 | 235 | 2007 |
| Angiogenesis-related pathways in the pathogenesis of ovarian cancer NG Gavalas, M Liontos, SP Trachana, T Bagratuni, C Arapinis, C Liacos, ... International journal of molecular sciences 14 (8), 15885-15909, 2013 | 183 | 2013 |
| Systemic therapy in cervical cancer: 30 years in review M Liontos, A Kyriazoglou, I Dimitriadis, MA Dimopoulos, A Bamias Critical reviews in oncology/hematology 137, 9-17, 2019 | 180 | 2019 |
| Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer G Velimezi, M Liontos, K Vougas, T Roumeliotis, J Bartkova, M Sideridou, ... Nature cell biology 15 (8), 967-977, 2013 | 130 | 2013 |
| SRC-induced disassembly of adherens junctions requires localized phosphorylation and degradation of the rac activator tiam1 SA Woodcock, C Rooney, M Liontos, Y Connolly, V Zoumpourlis, ... Molecular cell 33 (5), 639-653, 2009 | 109 | 2009 |
| Advanced small cell lung cancer (SCLC): new challenges and new expectations N Tsoukalas, E Aravantinou-Fatorou, P Baxevanos, M Tolia, K Tsapakidis, ... Annals of translational medicine 6 (8), 2018 | 103 | 2018 |
| Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins M Sideridou, R Zakopoulou, K Evangelou, M Liontos, A Kotsinas, ... Journal of Cell Biology 195 (7), 1123-1140, 2011 | 99 | 2011 |
| Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non‐small cell lung cancer K Apostolopoulou, IS Pateras, K Evangelou, PK Tsantoulis, M Liontos, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2007 | 83 | 2007 |
| Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive … A Bamias, K Tzannis, LC Harshman, SJ Crabb, YN Wong, SK Pal, ... Annals of Oncology 29 (2), 361-369, 2018 | 82 | 2018 |
| JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer T Bagratuni, N Mavrianou, NG Gavalas, K Tzannis, C Arapinis, M Liontos, ... European Journal of Cancer 126, 125-135, 2020 | 67 | 2020 |
| The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis K Evangelou, J Bartkova, A Kotsinas, IS Pateras, M Liontos, G Velimezi, ... Cell Death & Differentiation 20 (11), 1485-1497, 2013 | 65 | 2013 |
| Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised … K Fizazi, G Kramer, JC Eymard, CN Sternberg, J De Bono, D Castellano, ... The Lancet Oncology 21 (11), 1513-1525, 2020 | 64 | 2020 |
| Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer A Andrikopoulou, E Zografos, M Liontos, K Koutsoukos, MA Dimopoulos, ... Clinical breast cancer 21 (3), e212-e219, 2021 | 63 | 2021 |
| Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas M Liontos, K Niforou, G Velimezi, K Vougas, K Evangelou, ... The American journal of pathology 175 (1), 376-391, 2009 | 58 | 2009 |
Meletios Athanasios DimopoulosNational and Kapodistrian University of Athens, School of MedicineVerified email at med.uoa.gr
